182 related articles for article (PubMed ID: 22289074)
1. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.
Sclar DA; Robison LM; Castillo LV; Schmidt JM; Bowen KA; Oganov AM; Skaer TL; Kogut SJ
Headache; 2012 Feb; 52(2):198-203. PubMed ID: 22289074
[TBL] [Abstract][Full Text] [Related]
2. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome.
Sclar DA; Robison LM; Skaer TL
Headache; 2008 Jan; 48(1):126-9. PubMed ID: 18005139
[TBL] [Abstract][Full Text] [Related]
3. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits.
Molina KC; Fairman KA; Sclar DA
Drug Healthc Patient Saf; 2018; 10():37-43. PubMed ID: 29760569
[TBL] [Abstract][Full Text] [Related]
4. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.
Orlova Y; Rizzoli P; Loder E
JAMA Neurol; 2018 May; 75(5):566-572. PubMed ID: 29482205
[TBL] [Abstract][Full Text] [Related]
5. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.
Evans RW; Tepper SJ; Shapiro RE; Sun-Edelstein C; Tietjen GE
Headache; 2010 Jun; 50(6):1089-99. PubMed ID: 20618823
[TBL] [Abstract][Full Text] [Related]
6. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome?
Evans RW
Headache; 2008 Apr; 48(4):639-40. PubMed ID: 18377388
[No Abstract] [Full Text] [Related]
7. Do triptan antimigraine medications interact with SSRI/SNRI antidepressants? What does your decision support system say?
Kogut SJ
J Manag Care Pharm; 2011 Sep; 17(7):547-51. PubMed ID: 21870895
[TBL] [Abstract][Full Text] [Related]
8. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.
Evans RW
MedGenMed; 2007 Sep; 9(3):48. PubMed ID: 18092054
[TBL] [Abstract][Full Text] [Related]
9. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?
Wenzel RG; Tepper S; Korab WE; Freitag F
Ann Pharmacother; 2008 Nov; 42(11):1692-6. PubMed ID: 18957623
[TBL] [Abstract][Full Text] [Related]
10. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters.
Sclar DA; Robison LM; Skaer TL; Galin RS
Int J Psychiatry Med; 1998; 28(4):407-19. PubMed ID: 10207740
[TBL] [Abstract][Full Text] [Related]
11. Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report.
Meng Y; Yuen J
J Pharm Pract; 2023 Jun; 36(3):705-710. PubMed ID: 34962845
[No Abstract] [Full Text] [Related]
12. Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgical Patients.
Smith MM; Smith BB; Lahr BD; Nuttall GA; Mauermann WJ; Weister TJ; Dearani JA; Barbara DW
Anesth Analg; 2018 Jun; 126(6):1859-1866. PubMed ID: 29210786
[TBL] [Abstract][Full Text] [Related]
13. Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice.
Tepper SJ
Headache; 2012 Feb; 52(2):195-7. PubMed ID: 22221260
[No Abstract] [Full Text] [Related]
14. The serotonin syndrome, triptans, and the potential for drug-drug interactions.
Shapiro RE; Tepper SJ
Headache; 2007 Feb; 47(2):266-9. PubMed ID: 17300366
[TBL] [Abstract][Full Text] [Related]
15. Interaction between tramadol and selective serotonin reuptake inhibitors: are doctors aware of potential risks in their prescription practice?
Spies PE; Pot JLWH; Willems RPJ; Bos JM; Kramers C
Eur J Hosp Pharm; 2017 Mar; 24(2):124-127. PubMed ID: 31156918
[TBL] [Abstract][Full Text] [Related]
16. SSRI/SNRI -induced Hyponatremia: A Case Series of 26 Patients in a Single Institution from 2018 to 2020.
Zhao Z; Zhao F; Jin P; Hu X; Tian C; Liu D; Zhang Y
Psychiatr Q; 2023 Jun; 94(2):113-125. PubMed ID: 36913163
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study.
Leong C; Alessi-Severini S; Enns MW; Nie Y; Sareen J; Bolton J; Prior HJ; Chateau D
J Clin Psychopharmacol; 2017 Jun; 37(3):332-340. PubMed ID: 28383363
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy.
Karkow DC; Kauer JF; Ernst EJ
J Clin Psychopharmacol; 2017 Oct; 37(5):518-523. PubMed ID: 28796019
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA.
Miller M; Pate V; Swanson SA; Azrael D; White A; Stürmer T
CNS Drugs; 2014 Jan; 28(1):79-88. PubMed ID: 24146116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
